BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Korn EL, Freidlin B. Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. J Natl Cancer Inst 2017;109. [PMID: 28376148 DOI: 10.1093/jnci/djx013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Van Norman GA. Phase II Trials in Drug Development and Adaptive Trial Design. JACC Basic Transl Sci 2019;4:428-37. [PMID: 31312766 DOI: 10.1016/j.jacbts.2019.02.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
2 Alessandrino F, Smith DA, Spierling A, Kikano E, Somarouthu B, Tirumani SH, Ramaiya NH. Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask. AJR Am J Roentgenol 2021;216:1099-111. [PMID: 33594911 DOI: 10.2214/AJR.20.22852] [Reference Citation Analysis]
3 Ryan EG, Lamb SE, Williamson E, Gates S. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study. Trials 2020;21:83. [PMID: 31937341 DOI: 10.1186/s13063-019-4021-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Wang H, Yee D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Curr Breast Cancer Rep 2019;11:303-10. [PMID: 33312344 DOI: 10.1007/s12609-019-00334-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bhattacharyya A, Rai SN. Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design. Contemp Clin Trials Commun 2019;15:100378. [PMID: 31289760 DOI: 10.1016/j.conctc.2019.100378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Garcia Barrado L, Burzykowski T. Bayesian biomarker-driven outcome-adaptive randomization with an imperfect biomarker assay. Clin Trials 2021;18:137-46. [PMID: 33231131 DOI: 10.1177/1740774520964202] [Reference Citation Analysis]
7 Nikkho S, Fernandes P, White RJ, Deng CC, Farber HW, Corris PA. Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. Pulm Circ 2020;10:2045894020941491. [PMID: 33282181 DOI: 10.1177/2045894020941491] [Reference Citation Analysis]
8 Cristea IA, Naudet F, Ioannidis JPA. Preserving equipoise and performing randomised trials for COVID-19 social distancing interventions. Epidemiol Psychiatr Sci 2020;29:e184. [PMID: 33109299 DOI: 10.1017/S2045796020000992] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Webster J, Exley J, Copestake J, Davies R, Hargreaves J. Timely evaluation in international development. Journal of Development Effectiveness 2018;10:482-508. [DOI: 10.1080/19439342.2018.1543345] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Fountzilas E, Tsimberidou AM. Overview of precision oncology trials: challenges and opportunities. Expert Rev Clin Pharmacol 2018;11:797-804. [PMID: 30044653 DOI: 10.1080/17512433.2018.1504677] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
11 Garralda E, Dienstmann R, Piris-Giménez A, Braña I, Rodon J, Tabernero J. New clinical trial designs in the era of precision medicine. Mol Oncol 2019;13:549-57. [PMID: 30698321 DOI: 10.1002/1878-0261.12465] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 15.7] [Reference Citation Analysis]
12 Tatsioni A, Siountri I, Tsamoulis D, Vafeidou K. Clinical trials during pandemic in primary care: Low number and low validity after one-year experience. Eur J Gen Pract 2021;27:274-6. [PMID: 34633269 DOI: 10.1080/13814788.2021.1986279] [Reference Citation Analysis]
13 Giovagnoli A. The Bayesian Design of Adaptive Clinical Trials. Int J Environ Res Public Health 2021;18:E530. [PMID: 33435249 DOI: 10.3390/ijerph18020530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Meyer EL, Mesenbrink P, Dunger-baldauf C, Fülle H, Glimm E, Li Y, Posch M, König F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics 2020;42:1330-60. [DOI: 10.1016/j.clinthera.2020.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
15 Chen D, Qi EY. Innovative highlights of clinical drug trial design. Transl Res 2020;224:71-7. [PMID: 32504825 DOI: 10.1016/j.trsl.2020.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S. Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Curr Treat Options Oncol 2018;19:11. [PMID: 29488033 DOI: 10.1007/s11864-018-0524-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Grayling MJ, Wheeler GM. A review of available software for adaptive clinical trial design. Clin Trials 2020;17:323-31. [PMID: 32063024 DOI: 10.1177/1740774520906398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Le-Rademacher J, Dahlberg S, Lee JJ, Adjei AA, Mandrekar SJ. Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. J Thorac Oncol 2018;13:1625-37. [PMID: 30194034 DOI: 10.1016/j.jtho.2018.08.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Bosco A, Paulauskaite L, Hall I, Crabtree J, Soni S, Biswas A, Cooper V, Poppe M, King M, Strydom A, Crawford MJ, Hassiotis A. Process evaluation of a randomised controlled trial of PBS-based staff training for challenging behaviour in adults with intellectual disability. PLoS One 2019;14:e0221507. [PMID: 31437228 DOI: 10.1371/journal.pone.0221507] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
20 Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther 2021;27:885-907. [PMID: 34461278 DOI: 10.1016/j.jtct.2021.08.016] [Reference Citation Analysis]
21 Ji L, McShane LM, Krailo M, Sposto R. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial. Clin Trials 2019;16:599-609. [PMID: 31581815 DOI: 10.1177/1740774519875969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Mazzarella L, Morganti S, Marra A, Trapani D, Tini G, Pelicci P, Curigliano G. Master protocols in immuno-oncology: do novel drugs deserve novel designs? J Immunother Cancer 2020;8:e000475. [PMID: 32238471 DOI: 10.1136/jitc-2019-000475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
23 Tini G, Duso BA, Bellerba F, Corso F, Gandini S, Minucci S, Pelicci PG, Mazzarella L. Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness. Front Med (Lausanne) 2020;7:367. [PMID: 32695791 DOI: 10.3389/fmed.2020.00367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
24 Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J 2019;53:1801908. [PMID: 30545975 DOI: 10.1183/13993003.01908-2018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 25.0] [Reference Citation Analysis]
25 Xia F, George SL, Ning J, Li L, Huang X. A Signature Enrichment Design with Bayesian Adaptive Randomization. J Appl Stat 2021;48:1091-110. [PMID: 34024982 DOI: 10.1080/02664763.2020.1757048] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Beaulieu-Jones BK, Finlayson SG, Yuan W, Altman RB, Kohane IS, Prasad V, Yu KH. Examining the Use of Real-World Evidence in the Regulatory Process. Clin Pharmacol Ther 2020;107:843-52. [PMID: 31562770 DOI: 10.1002/cpt.1658] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
27 Peters GW, Tao W, Wei W, Miccio JA, Jethwa KR, Cecchini M, Johung KL. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. Oncologist 2021;26:660-7. [PMID: 33728733 DOI: 10.1002/onco.13759] [Reference Citation Analysis]
28 Ji L, McShane LM, Krailo M, Sposto R. Rejoinder. Clin Trials 2019;16:613-5. [PMID: 31581812 DOI: 10.1177/1740774519875971] [Reference Citation Analysis]
29 Korn EL, Freidlin B. Time trends with response-adaptive randomization: The inevitability of inefficiency. Clin Trials 2022;:17407745211065762. [PMID: 34991348 DOI: 10.1177/17407745211065762] [Reference Citation Analysis]